Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -16.58% is 87% above its 5-year average of -132.36%, near the high end of its 5-year range (-299.90%–46.70%).
76.59% above its 12-month average of -70.84%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -47.29%.
EBITDA MARGIN
-16.58%
EBITDA MARGIN AVG TTM
-70.84%
EBITDA MARGIN AVG 3Y
-116.08%
EBITDA MARGIN AVG 5Y
-132.36%
EBITDA MARGIN AVG 10Y
-336.61%
EBITDA MARGIN AVG 15Y
-336.61%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+76.59%
CURRENT VS 3Y AVG
+85.72%
CURRENT VS 5Y AVG
+87.47%
CURRENT VS 10Y AVG
+95.07%
CURRENT VS 15Y AVG
+95.07%
CURRENT VS 20Y AVG
N/A
Assembly Biosciences, Inc.
Market Cap
$443.61M
EBITDA Margin
-16.58%
TTM Avg
-70.84%
3Y Avg
-116.08%
5Y Avg
-132.36%
Market Cap
$434.84M
EBITDA Margin
-184.73%
TTM Avg
-138.06%
3Y Avg
-2467.18%
5Y Avg
-2497.88%
Market Cap
$437.37M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$457.20M
EBITDA Margin
-1349.20%
TTM Avg
-1349.20%
3Y Avg
-1349.20%
5Y Avg
-1349.20%
Market Cap
$462.71M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$465.59M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$472.58M
EBITDA Margin
-3.52%
TTM Avg
-5.19%
3Y Avg
-11.78%
5Y Avg
-23.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $443.61M | -16.58% | -70.84% | -116.08% | -132.36% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $434.84M | -184.73% | -138.06% | -2467.18% | -2497.88% |
| Editas Medicine, Inc. (EDIT)vs › | $437.37M | -232.13% | -495.69% | -578.57% | -532.48% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $457.20M | -1349.20% | -1349.20% | -1349.20% | -1349.20% |
| NRC Health (NRC)vs › | $462.23M | 21.99% | 25.40% | 28.98% | 31.97% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $462.71M | -31.76% | -31.76% | -31.76% | -31.76% |
| Kamada Ltd. (KMDA)vs › | $463.29M | 22.80% | 21.92% | 17.96% | 15.83% |
| NeoGenomics, Inc. (NEO)vs › | $465.59M | 0.24% | -1.36% | -6.49% | -5.53% |
| Cerus Corporation (CERS)vs › | $472.58M | -3.52% | -5.19% | -11.78% | -23.46% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | 39.39% | 8.38% | 8.38% | 8.38% |
Gross Margin
99.8%
EBITDA Margin
-16.6%
Operating Margin
-11.8%
Net Margin
-0.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -47.29% |
| 2026-03-31 | -138.12% |
| 2025-12-31 | 46.70% |
| 2025-09-30 | -100.57% |
| 2025-06-30 | -114.91% |
| 2025-03-31 | -105.19% |
| 2024-12-31 | -156.31% |
| 2024-09-30 | -159.58% |
| 2024-06-30 | -142.63% |
| 2024-03-31 | -184.91% |
| 2023-12-31 | -174.05% |
| 2021-09-30 | -299.90% |
| 2020-12-31 | -3792.48% |
| 2020-09-30 | -11.21% |
| 2020-06-30 | 17.02% |
| 2020-03-31 | -675.79% |
| 2019-12-31 | -599.39% |
| 2019-09-30 | -611.58% |
| 2019-06-30 | -635.55% |
| 2019-03-31 | -725.89% |
| 2018-12-31 | -700.14% |
| 2018-09-30 | -522.98% |
| 2018-06-30 | -839.75% |
| 2018-03-31 | -462.94% |
| 2017-12-31 | -367.52% |
| 2017-09-30 | -466.55% |
| 2017-06-30 | -572.89% |
| 2017-03-31 | -2030.76% |
| 2010-12-31 | 0.02% |
